Meeting
2022 ASCO Annual Meeting
[18F]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed.
Authors
Preetha Aravind
Imperial College London, London, United Kingdom
Preetha Aravind , Sanjay Popat , Tara D. Barwick , Neil Soneji , Mark Lythgoe , Jingky Lozano-kuehne , Katherina Bernadette Sreter , Mattias Bergqvist , Neva H. Patel , Eric O. Aboagye , Laura M. Kenny
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
NCRI UK badge 9249
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3070)
DOI
10.1200/JCO.2022.40.16_suppl.3070
Abstract #
3070
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
18-FLT-PET/CT as an imaging biomarker in patients with ASS1-deficient thoracic cancers treated with ADI-PEG20, pemetrexed and cisplatin.
First Author: Peter Wojciech Szlosarek
Poster
2015 ASCO Annual Meeting
Pharmacodynamic (PD) assessment using FLT-PET/CT imaging in patients treated with an interrupted high-dose axitinib schedule.
First Author: Ludimila Cavalcante
Poster
2023 ASCO Annual Meeting
Large-scale comparative analysis of clinico-genomic characteristics, treatment outcomes and resistant mechanisms of ALK/ROS1/RET-rearranged non-small cell lung cancer (NSCLC) in a nationwide genomic screening project (LC-SCRUM-Asia/TRY).
First Author: Yosuke Kagawa
Poster
2022 ASCO Annual Meeting
AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC.
First Author: Sanjay Popat